The Story Behind The Media

The founders of RoosterBio realized that redundant efforts were impeding the regenerative medicine sector. They hypothesized that well-characterized, off-the-shelf MSCs would standardize the supply chain to accelerate cell therapies through preclinical and clinical studies. In turn, our customers’ success would unlock reliable patient care that delivers on the promises of regenerative medicine. By cooperating as a network of specialized experts, our community would thus de-risk the cellular therapy development pipeline. The RoosterBio system fuels the rapid commercialization of scalable regenerative cures. Regulatory expertise, cGMP manufacturing, and Type II MasterFile with the FDA save customers’ work. RoosterBio's ultimate goal is approved, useful cell therapies that benefit patients.

Learn more about our efforts to solve today’s problems in regenerative medicine with efficient collaboration.